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Abstract We have cloned and overexpressed rat 4-hydroxy- 
phenylpyruvate dioxygenase (4HPPD) in Escherichia coil The 
soluble, active recombinant enzyme was shown to contain both 
4HPPD and ¢x-ketoisocaproate dioxygenase (¢zKICD) activity. 
However, upon truncation of the 14 amino acids at the C- 
terminus by site-directed mutagenesis, the resulting mutant 
enzyme (rat F antigen) exhibited complete loss of 4HPPD and 
ff~KICD activities. This finding suggests that the C-terminal 
extension domain plays an essential role in the catalytic activity 
of the enzyme. 
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Database analysis and multiple alignment of amino acid 
sequences revealed that rat F antigen (RFA) exhibits a high 
degree of homology (> 90%) with 4HPPD from a variety of 
species. RFA is a protein of about 43 kDa found predomi- 
nantly in the hepatic cytoplasm of mammals. First identified 
in 1968, it has been extensively studied as a model of tolerance 
but to date, its function is still unknown [10 12]. One impor- 
tant difference between RFA and mammalian 4HPPD is the 
apparently shorter C-terminus of RFA,  but despite this, it has 
been postulated that RFA is a species variant of 4HPPD or is 
in fact 4HPPD. Herein, we report that when active recombi- 
nant 4HPPD was converted to RFA by site-directed mutagen- 
esis, the resulting mutant showed complete loss of activity. 
2. Materials and methods 
1. Introduction 
4-Hydroxyphenylpyruvate dioxygenase (4HPPD) is an en- 
zyme involved in the metabolism of tyrosine, converting 4- 
hydroxyphenylpyruvate (4HPP) to homogentisate through 
decarboxylation and hydroxylation. The enzyme has been 
purified from porcine [1], human [2] and avian livers [3] as 
well as Pseudomonas p. [4]. In mammalian species, the en- 
zyme exists in dimeric form, whereas the Pseudomonas enzyme 
was shown to be a tetramer of 150 kDa. 
4HPPD is a non-heme dioxygenase that requires Fe 2+, 02, 
DTT and ascorbate for its activity. As an important enzyme 
in the degradation pathway of tyrosine, inhibition of 4HPPD 
has been used in the treatment of tyrosinaemia (type I) and 
liver cirrhosis [5]. It has also been demonstrated that 4HPPD 
is involved in the formation of melanin-like pigment in marine 
bacteria [6,7]. Most interestingly, we recently found that 
4HPPD purified from rat liver is capable of catalysing the 
conversion of ~¢-ketoisocaproate (ecKIC) to [3-hydroxyisova- 
leric acid [8]. 
In the liver, the cytosolic conversion of aK IC  to ]3-hydro- 
xyisovaleric acid was thought to be performed by another 
enzyme, c¢-ketoisocaproate dioxygenase (ctKICD), a non- 
heme dioxygenase that also requires Fe 2+, 02, DTT and as- 
corbate for activity. From our studies with the recombinant 
rat 4HPPD, we have confirmed that the activities of both 
4HPPD and aK ICD are due to a single enzyme [9]. 
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2.1. cDNA library screening 
A ?~ ZAP II rat liver cDNA library (Sprague-Dawley, male, 6 
months old from Stratagene) was screened for 4HPPD with the poly- 
merase chain reaction (PCR), modified from the methods of Takumi 
and Lodish [13] as described previously [9]. Primers used for screening 
were designed according to the incomplete cDNA sequence of RFA 
[12]. Primers used were 5'GTGGTCAGTCATGTCATCAAGCAA3' 
(forward) (169-192) and 5'ACAGAGAGTTGAAGTTACCTG- 
CTCC3' (reverse) (1102 1078). PCR reactions were carried out using 
Taq polymerase (Pharmacia) for 30 cycles: the first cycle was 94°C, 
5 min, 55°C, 1 min, and 72°C, 1 min. The following 29 cycles were 
94°C, 1 min, 55°C, 1 rain and 72°C, 1 min. 
60000 plaque-forming units (pfu) were initially aliquoted from the 
library and divided into 20 pools, each of 3000 pfu. These pools were 
amplified and screened by PCR. Positive pools that showed a band of 
correct molecular weight as judged by agarose gel electrophoresis were 
further subdivided into subpools, each of 200 pfu. Reamplification, 
screening and subdivision were repeated to the level of a single plaque. 
A clone with an estimated insert of 1.3 kb was selected for in vivo 
excision. Single stranded DNA rescue was performed essentially ac- 
cording to the protocols provided by Stratagene (Stratagene, USA). 
2.2. Subcloning into expression vector 
Incomplete 4HPPD cDNA in pBluescript vector was amplified by 
PCR for the purpose of subcloning using Vent polymerase (New 
England Biolabs). The forward primer 5'GATCGACATATGACC- 
ACCTACTGGGACAAAGGACCAGAGCCTGAGAGAGGCCGG- 
TTCCTC3' and reverse primer 5'GATCGAGGATCCTCA- 
TTACATTCCAGACCTCACACCGTTGGTCTC3' contained nu- 
cleotides introduced to give additional amino acids at 5' end (bold). 
In addition, NdeI and BamHI restriction sites (underlined) were added 
at the 5' and 3' ends for ease of subcloning. PCR was performed for 
30 cycles and the DNA fragment was isolated and cloned into a ptrc 
vector (termed pHPD). Before expression, the recombinant plasmid 
was sequenced in both strands to confirm no unwanted mutation had 
been introduced by PCR. 
Abbreviations: DTT, dithiothreitol; 4HPP, 4-hydroxyphenylpyruvate; 
4HPPD, 4-hydroxyphenylpyruvate dioxygenase; ecKIC, ot-ketoiso- 
caproate; ctKICD, a-ketoisocaproate dioxygenase; RFA, rat F 
antigen. 
2.3. Expression of 4HPPD 
Clones in XL-l Blue MRF' were grown in 2TY broth supplemen- 
ted with 34 lag/ml chloramphenicol at 27°C with shaking at 250 rpm 
until OO61)ll reached 1.5. Isopropyl-~-D-thiogalactopyranoside (IPTG) 
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was added to a final concentration of 0.3 mM and the cultures were 
incubated for another 15 h. Cultures were centrifuged at 10 000 × g for 
5 min. Cell pellets were resuspended in 50 mM Tris-HC1 buffer, pH 
8.0 with 1 mM EDTA. Cells lysis was carried out with sonication for 
3 times (10 s) with a 15 s interval between repeats. Cell debris was 
removed by centrifugation at 10000×g for 25 min and the super- 
natants were collected for protein purification or enzyme assay. 
2.4. Protein pur(fication 
4HPPD was precipitated from the above supernatant by adding 
ammonium sulfate (30% w/v) followed by stirring at 4°C for 1 h 
and centrifugation at 10 000 × g for 20 min. The pellet was redissolved 
in 50 mM Tris-HC1, pH 8.0 containing 1 mM EDTA (buffer A) 
before loading the resultant solution onto a DEAE Sepharose fast 
flow column pre-equilibrated with buffer A. After washing the column 
with 2 column volumes of buffer A, the absorbed proteins remaining 
on the column were eluted by running a linear gradient from 0 to 25% 
buffer B (1 M NaC1 in buffer A). 4HPPD was typically eluted at 0.18 
M NaC1. 
2.5. Enzyme assay 
o~KICD activity was determined essentially according to the method 
described by Sabourin and Bieber [14]. A typical assay would consist 
of a final volume of 0.4 ml: 0.10 M Tris-maleate buffer, pH 6.0, 1 mM 
FeSO1, 0.5 mM ascorbic acid, 1 mM DTT, 1 mM [1-14C]c~KIC 
(40000 dpm/16.5 pl per assay), and 40 gl purified enzyme or crude 
lysates (protein concentration 2.0 2.5 mg/ml). The mixture was tirst 
preincubated for 30 min at 27°C without the substrate, c~KIC. As 
negative controls, lysates of host cell without the plasmid, or Milli- 
Q water were used for incubation. [1-14C]c~KIC was added to initiate 
the reaction after 30 min and the 11CO 2 released was absorbed with 
0.2 ml Hyamine solution (ICN Radiochemicals, Irvine, CA) in an 
Eppendorf overhanging the reaction mixture. After 1 h, 0.2 ml of 
20% TFA was added to terminate the reaction and an additional 1 h 
was allowed for the absorption of 14CO2. The Eppendorf containing 
the Hyamine solution was transferred to a scintillation vial, to which 
was then added 10 ml of Optiphase 'Safe' scintillation fluid (EG&G, 
UK) and the vial was counted for 1~C activity. 
2.6. Site-directed mutagenesis 
Site-directed mutagenesis was performed using a Pharmacia U.S.E. 
kit according to the manufacturer's instructions. The oligonucleotide 
used to generate C-terminal deletion mutant protein (rat F antigen) 
from pHPD was 5'CCAAGCTTCCCGGGATTCAGTGAGGTT- 
AACCCCGTAGGGCTTGCTCCTC3'. The mutant (termed pRFA) 
was subjected to sequencing in both orientations to confirm the in- 
troduction of the mutation at the site desired. 
3. Results and discussion 
3.1. Cloning of 4HPPD from rat 
The 4HPPD fragment isolated from Sprague-Dawley 
eDNA revealed an open reading frame of 1155 nucleotides, 
lacking the 5' end. The nucleotide sequence and deduced ami- 
no acids were shown to be almost identical with that of rat F 
antigen published by Gershwin et al. [12], with the exception 
of four base substitutions and a single base deletion. One base 
substitution is at position 26, where the cytosine (C) in RFA 
cDNA is replaced by an adenosine (A) (nucleotide position 
according to RFA sequence published by Gershwin et al. 
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Fig. 1. Sequence alignment of the C-terminals of (1) rat F antigen 
(RFA), (2) mouse F antigen (tuFA) and (3) 4-hydroxyphenylpyru- 
vate dioxygenase (4HPPD) described here. In RFA, the thymidine 
(T) insertion at position 1138 introduced a termination codon (un- 
derlined). Consequently, the peptide lacks the final 14 amino acid 
residues compared with 4HPPD. 
[12]). The second substitution is at position 28 (guanosine 
(G) instead of adenosine (A)), which changes the amino 
acid lysine to glutamic acid. The other two substitutions are 
both third base substitutions at positions 60 (thymidine (T) 
for cytosine (C)) and 729 (adenosine (A) for guanosine (G)), 
making no difference to the amino acids as coded for by the 
published RFA sequence. Nonetheless, the single base (thymi- 
dine) deletion at position 1138 eliminates the stop codon pres- 
ent in RFA cDNA. This enables a further 14 amino acids to 
be translated at the C-terminal (Fig. 1). 
So far, a complete rat 4HPPD has never been isolated. 
Judging from the amino acid sequence of mouse 4HPPD 
[15] and RFA published [12], it was decided to overexpress 
the protein in E. coli with the N-terminus according to the 
cDNA sequence of RFA [12]. An additional 2 amino acids 
derived from mouse (namely Thr, Thr) were added down- 
stream of the initiation codon. 
3.2. Expression and purification of 4HPPD 
When induced, SDS-PAGE analysis revealed an overex- 
pressed protein of 45 kDa in cell lysates from clones contain- 
ing the 4HPPD plasmid. This 45 kDa protein was not found 
in control host cell XL-1 Blue MRF '  (Fig. 2). The recombi- 
nant 4HPPD was purified to > 90% purity after ammonium 
sulfate precipitation and DEAE chromatography, with sub- 
stantial oss of activity (unpublished). The Mr of the purified 
recombinant protein measured by electrospray mass spec- 
trometry was 45085 + 0.8 (calc. Mr 45,082). N-terminal se- 
quencing confirmed that the first methionine had been cleaved 
off'. 
3.3. 4HPPD activity 
As noticed by other groups cloning 4HPPD from Strepto- 
myces avermitilis and melA gene from Shewanella colwelliana, 
E. coli harbor ing the plasmid containing the 4HPPD gene 
produced a characteristic brownish pigment after overnight 
Table 1 
Assays for o~KICD and 4HPPD activity 
pHPD pRFA Host cell Milli-Q water 
e~KICD assay: ~4CO2 released (cpm) 3571 204 191 213 
4HPPD assay: pigment production +++ - - NA 
ccKICD activity was measured by the release of 14CO2 from c~-[l-t4C]ketoisocaproate. Th  values above are the averages of 5 readings for pHPD 
and pRFA, and duplicate for negative controls. 4HPPD assay: +++, strong brownish pigment; - ,  no brownish pigment in culture. NA, not 
applicable. 
M.-H. Lee et al./FEBS Letters 393 (1996) 269-272 
1 2 3 4 
kDa 
66-  





Fig. 2. Expression of 4HPPD and RFA in E. coli. Cells were in- 
duced and harvested as described in Section 2. Supernatants of solu- 
ble proteins were subjected to SDS-PAGE (12.5%) analysis and 
stained with Coomassie Blue. Lanes: 1, molecular weight markers; 
2, host cell XL-1 Blue MRF'; 3, pHPD; 4, pRFA. 
culture both on solid and liquid media [16,7]. The authors 
found that the intensity of this pigment could be increased 
by the addition of L-tyrosine. It is known that E. coli contains 
transaminases capable of converting L-tyrosine to 4-hydroxy- 
phenylpyruvate (4HPP), the substrate of 4HPPD, which in 
turn, could be further catalysed by the recombinant 4HPPD 
to homogentisate (HGA). It was thus postulated that the 
brownish pigment produced was either ochronitic acid or a 
melanin-like substance, a product of the oxidation and poly- 
merization of HGA. Thus, the presence of active 4HPPD in 
E. coli could be judged by the formation of this pigment. In 
our laboratory, we too noticed that the pHPD clone also 
produced similar brownish pigment, especially when grown 
in rich media. So far, the production of this pigment has 
been reported in 4HPPD clones of microorganisms like She- 
wanella colwelliana and S. avermitilis. In the mammalian en- 
zyme, a direct link between 4HPPD and the production of this 
pigment has thus also been established. 
pRFA showed the same level of protein expression and 
solubility profile as pHPD upon induction with IPTG. Never- 
theless, no brownish pigment formation could be observed 
even after a prolonged growing period in e-tyrosine nriched 
medium (Table 1). The presence of RFA in this induced cul- 
ture was confirmed by SDS-PAGE analysis. The data indi- 
cates that pRFA is inactive, i.e. incapable of converting 4HPP 
to HGA. 
3.4. otKICD activity 
We previously reported that native rat 4HPPD also showed 
c~KICD activity [8]. In the recombinant clone, it was noted 
that E. coil lysates harboring the 4HPPD plasmid had shown 
high c~KICD activity. Lysates of host cell, XL-1 Blue MRF '  
without plasmid were inactive. Since we found that purified 
4HPPD from DEAE chromatography was less active and 
rather unstable in storage, lysates of pHPD and pRFA with 
the same protein concentrations were used for aK ICD assay 
throughout his work. As shown in Table 1, 4HPPD is com- 
pletely devoid of c~KICD activity when mutated to RFA.  
Rat F antigen was first identified in 1968 and has been 
studied extensively over the years because of its interesting 
properties as an alloantigen. When mice of responder strains 
are immunized with liver lysates from other strains, the anti- 
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body produced reacts against not only the immunogen, but 
also against its own allelic form of the protein. Early studies 
had concentrated on the protein per se. Thus cloning of rat F 
antigen was first reported by Gershwin et al. [12] in 1987 with 
the protein being overexpressed in E. coli as a fusion protein 
with [3-galactosidase. However, no mass spectrometry or pro- 
tease digestion has been reported on the recombinant protein 
to confirm the exact translation of the proposed cDNA. 
Mouse F antigen, on the other hand, was isolated by Scho- 
field et al. [17] using the PCR method, based on the rat cDNA 
sequence published earlier [12]. The primers were designed 
based on the 5' and 3' ends of rat F antigen. The mouse F 
antigen was amplified from first strand cDNA using Taq poly- 
merase and the amplicon subcloned and sequenced. In mouse 
F antigen, it was postulated by Schofield et al. that the C- 
terminus was identical to that of rat. However, it should be 
noted that in the process of cloning, the same laboratory did 
observe that mouse F antigen had an apparent deletion of the 
first base of the stop codon [17]. Nonetheless, this was inter- 
preted by the authors as a PCR artefact introduced by Taq 
polymerase. 
The possible role of rat F antigen only came to light when 
4HPPD from Streptomyces, human and porcine were cloned 
[16,18,19]. Sequence comparison showed that RFA bore a 
striking similarity to 4HPPD isolated from these organisms. 
In this paper, we have demonstrated that rat F antigen is 
inactive with respect to c~KICD and 4HPPD activities. It is 
clear that the difference between rat 4HPPD and RFA cDNA 
lies solely at the termination codon. When compared with the 
cDNA of active 4HPPD in this work, the RFA cDNA se- 
quence published by Gershwin et al. was shown to have an 
insertion of thymidine (T), which introduced a termination 
codon at position 1138, causing the protein to be shortened 
by 14 residues. 4HPPD is known to be a key enzyme in the 
catabolism of amino acid tyrosine and deficiency of this en- 
zyme causes hypertyrosinaemia. On the other hand, evidence 
that RFA plays a role in regulating the catabolic function of 
4HPPD or any other activity has not been found. We thus 
conclude that the previously isolated RFA cDNA could be a 
mutated 4HPPD gene which encodes for an incomplete n- 
zyme, or could represent an artefact introduced during clon- 
ing and sequencing. Currently, we are investigating the rat 
genomic DNA in order to further our understanding of the 
relationship between RFA and 4HPPD. 
Acknowledgements." Wewould like to acknowledge Dr. R.T. Aplin for 
his excellent support in mass spectrometry and A.C. Willis for N- 
terminal sequencing. We thank D.J. Hart (New Chemistry Labora- 
tory, Oxford) for ptrc vector and his expert advice on cloning and 
protein expression. We would also like to thank Prof. V. De Luca 
(University of Montreal, Canada) for useful discussion on this work. 
References 
[1] Buckthal, D.J., Roche, P.A., Moorehead, T.J., Forbes, B.J.R. 
and Hamilton, G.A. (1987) Methods Enzymol. 142, 132-138. 
[2] Lindstedt, S. and Odelhog, B. (1987) Methods Enzymol. 42, 139 
142. 
[3] Fellman, J.H. (1987) Methods Enzymol. 142, 148 154. 
[4] Lindstedt, S. and Odelhog, B. (1987) Methods Enzymol. 142, 
143 148. 
[5] Lindstedt, S., Holme, E., Lock, E.A., Hjalmarson, O. and 
Strandvik, B. (1992) Lancet 340, 813-817. 
[6] Coon, S.L., Kotob, S., Jarvis, B.B., Wang, S., Fuqua, W.C. and 
Weiner, R.M. (1994) Appl. Environ. Microbiol. 60, 30063010. 
272 
[7] Ruzafa, C., Solano, F. and Sanchez-Amat, A. (1994) FEMS Mi- 
crobiol. Lett. 124, 179 184. 
[8] Baldwin, J.E., Crouch, N.P., Fujishima, Y., Lee, M.H., MacKin- 
non, C.H., Pitt, J.P.N. and Willis, A.C. (1995) Bioorg. Med. 
Chem. Lett. 5, 1255 1260. 
[9] Crouch, N.P., Baldwin, J.E., Lee, M.H., MacKinnon, C.H. and 
Zhang, Z.H. (1996) Bioorg. Med. Chem. Lett. 6, 1503 1506. 
[10] Fravi, G. and Lindenmann, J. (1968) Nature 218, 141 
[11] Lane, D.P. and Silver, D.M. (1976) Eur. J. Imrnunol. 6, 480485. 
[12] Gershwin, M.E., Coppel, R.L., Bearer, E., Peterson, M.G., Stnr- 
gess, A. and Mackay, I.R. (1987) J. Immunol. 139, 3828-3833. 
[13] Takumi, T. and Lodish, H.F. (1994) Biotechniques 17, 443 444. 
M.-H. Lee et al./FEBS Letters 393 (1996) 269 272 
[14] Sabourin, P.J. and Bieber, L.L. (1988) Methods Enzymol. 166, 
288-297. 
[15] Endo, F., Awata, H., Katoh, H. and Matsuda, I. (1994) Gen- 
Bank Accession no. D29987. 
[16] Denoya, C.D., Skinner, D.D. and Morgenstern, M.R. (1994) 
J. Bacteriol. 176, 5312 5319. 
[17] Schofield, J.P., Vijayakumar, R.K. and Oliveira, D.B.G. (1991) 
Eur. J. Immunol. 21, 1235-1240. 
[18] Ruetschi, U., Dellsen, A., Sahlin, P., Stenman, G., Rymo, L. and 
Lindstedt, S. (1993) Eur. J. Biochem. 213, 1081 1089. 
[19] Endo, F., Awata, H., Tanoue, A., Ishiguro, M., Eda, Y., Titani, 
K. and Matsuda, I. (1992) J. Biol. Chem. 267, 24235 24240. 
